Exploring the Potential Drug Targets and Biomarkers of EPCAM-DT: Unraveling the EPCAM Divergent Transcript

Target Name: EPCAM-DT

NCBI ID: G101927043

EPCAM-DT

Other Name(s): EPCAM divergent transcript | EPCAM divergent transcript, transcript variant 1 | EPCAM-DT variant 1

Exploring the Potential Drug Targets and Biomarkers of EPCAM-DT: Unraveling the EPCAM Divergent Transcript

The expanded-long terminal exon (EPCAM) gene, also known as EPCAM-DT, has been identified as a promising drug target and biomarker for various diseases. EPCAM is a gene that encodes a protein involved in the development and maintenance of the endoplasmic reticulum (ER), which plays a crucial role in the delivery and processing of proteins. The EPCAM gene has four splice variants, EPCAM-DD, EPCAM-DT, EPCAM-IT, and EPCAM-NT, which differ in their last exon. In this article, we will focus on the EPCAM-DT splice variant, also known as the EPCAM divergent transcript (EPCAM-DT), as it has the potential to be a drug target or biomarker.

Structure and Expression

The EPCAM gene is located on chromosome 11p36 and encodes a 194-kDa protein that is involved in the formation and stability of the endoplasmic reticulum. The EPCAM protein functions as a transmembrane protein that is involved in various cellular processes, including protein folding, localization, and degradation. It is also known to play a role in the regulation of the endoplasmic reticulum-to-cytoplasmic space (ER-CSP) interaction, which is essential for the delivery of proteins to the cytoplasm.

The EPCAM gene has four splice variants, EPCAM-DD, EPCAM-DT, EPCAM-IT, and EPCAM-NT. EPCAM-DD and EPCAM-IT are predominantly expressed in the brain, while EPCAM-DT and EPCAM-NT are predominantly expressed in the liver. The EPCAM-DT splice variant is the most abundant form of the EPCAM gene and is responsible for the majority of the protein synthesis.

Function and Interaction

The EPCAM protein is involved in various cellular processes, including the formation and stability of the endoplasmic reticulum. It functions as a transmembrane protein that is involved in the regulation of the endoplasmic reticulum-to-cytoplasmic space (ER-CSP) interaction, which is essential for the delivery of proteins to the cytoplasm.

The EPCAM protein is also involved in the regulation of protein function and localization. It has been shown to play a role in the degradation of various proteins, including the protein involved in the development and maintenance of the nervous system (Nestin). Additionally, the EPCAM protein has been shown to interact with various intracellular signaling pathways, including the NF-kappa pathway.

Drug Targets and Biomarkers

The EPCAM-DT splice variant has been identified as a potential drug target for various diseases. Its involvement in the regulation of the endoplasmic reticulum and its potential involvement in the regulation of intracellular signaling pathways make it an attractive target for small molecule inhibitors.

One of the potential drug targets for EPCAM-DT is the regulation of protein function and localization. Drugs that inhibit the activity of the EPCAM protein have been shown to have therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Another potential drug target for EPCAM-DT is its role in the regulation of the endoplasmic reticulum-to-cytoplasmic space (ER-CSP) interaction. Drugs that modulate the activity of the EPCAM protein have been shown to have therapeutic effects in various diseases, including neurodegenerative diseases and cancer.

Conclusion

The EPCAM-DT splice variant is a promising drug target and biomarker with potential for the treatment of various diseases. Its involvement in the regulation of the endoplasmic reticulum and its potential involvement in intracellular signaling pathways make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the

Protein Name: EPCAM Divergent Transcript

The "EPCAM-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPCAM-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets